CEACAM5 and breast cancer: The American Society of Clinical Oncology (ASCO) guidelines do not currently recommend the use of serum CEA and CA 15-3 for screening, diagnosis, staging, or routine surveillance of breast cancer patients after primary therapy [3, 4].